Fig. 1

Effect of empagliflozin (EMPA) on anthropomorphic and glucose measures in PCOS. Effect of EMPA on A body weight, B body mass index, C change in fat mass/lean mass between 12 and 16 weeks of age, D cumulative food intake, E glucosuria, and F net glucose balance at 3 weeks of EMPA. Data are expressed as mean ± SEM. Data were analyzed by two-way ANOVA with (D) or without (A–C, E, F) repeated measures, followed by Tukey post hoc tests. Significant interaction was observed for change in fat mass/lean mass, cumulative food intake, and glucosuria. *P < 0.05. n = 6–10 per group